06 August 2019 1 Min Read
GSK hands over work on potential Ebola vaccine to US’s Sabin institute
Enabling Sabin to build on the scientific progress GSK has delivered up to phase II lifts the likelihood the candidate vaccines may help prevent potential future outbreaks, GSK Vaccines says
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In